Treatment of familial hypercholesterolemia in children and adolescents: Effect of lovastatin

Pediatrics

Volumn 97, Issue 5, 1996, Pages 619-628

  Lambert, Marie ^a,c   Lupien, Paul J ^b   Gagné, Claude ^b   Lévy, Emile ^c   Blaichman, Shirley ^d   Langlois, Sylvie ^e,f   Hayden, Michael ^f   Rose, Vera ^g   Clarke, Joe T R ^g   Wolfe, Bernard M J ^h   Clarson, Cheril ⁱ   Parsons, Howard ^j   Stephure, David K ^j   Potvin, Diane ^k   Lambert, Jean ^k  

^a Medical Genetics Service   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁱ CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

adolescent; children; drug therapy; familial hypercholesterolemia; lovastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS A; ASPARTATE AMINOTRANSFERASES; CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LOVASTATIN; MALE; PATIENT COMPLIANCE; PLACEBOS; SAFETY;

EID: 9244246763     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989;9(suppl I):I-19-I-32
2. Newman WP III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314:138-144
3. Newman WP III, Wattigney W, Berenson, GS. Autopsy studies in US children and adolescents. Relationship of risk factors to atherosclerotic lesions. Ann NY Acad Sci. 1991;623:16-25
4. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. JAMA. 1990;264: 3018-3024
5. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89-525-584
6. American Academy of Pediatrics. Committee on Nutrition. Statement on cholesterol. Pediatrics. 1992;90:469-473
7. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill; 1989;48:1215-1250
8. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolemia treated with cholestyramine. Lancet 1980; 2:873-875
9. West RJ. Problems of long-term treatment in children with familial hypercholesterolemia. Prog Clin Biol Res. 1985;188:209-211
10. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr. 1993;122:477-482
11. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49
12. Bradford RH, Downton M, Chremos AN, et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med. 1993;118:850-855
13. Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-3961
14. Ma PTS, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, and inhibitor of cholesterol synthesis, induces mRNA for low-density lipoprotein receptor in livers of hamsters and rabbits Proc Natl Acad Sci USA. 1986;83:8370-8374
15. Raveh D, Israeli A, Arnon R, Eisenberg S. Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Atherosclerosis. 1990;82:19-26
16. Stein EA. Drug therapy in children and adolescents with familial hypercholesterolemia. Prog Clin Biol Res. 1988;255:273-280
17. Stein EA Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989;9(suppl I):I-145-I-151
18. Uauy R, Vega GL, Grundy SM, Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia. lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988;113:387-392
19. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children Lancet. 1992;339:1488
20. Lipid Research Clinics. Lipid Research Clinics Population Studies Data Book, 1: The Prevatence Study. Washington, DC: US Government Printing Office; 1980. US Dept of Health and Human Services publication NIH 80-1527
21. Adams CF Nutritive Value of American Foods in Common Units Washington, DC Agricultural Research Service, 1975 Agriculture handbook 456, US Department of Agriculture stock No. 0100-03184
22. Health and Welfare Canada. The Canadian Nutrient File. Ottawa, Canada: Health and Welfare Canada, Food Directorate, Health Protection Branch; 1986
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge Clin Chem. 1972,18:499-502
24. Ducharme JR, Forest MG Normal pubertal development. In: Bertrand J, Rappaport R, Sizonenko PC, eds. Pediatric Endocrinology: Physiology, Pathophysiology and Clinical Aspects. Baltimore, MD: Williams & Wilkins; 1993;27:372-386
25. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328:1213-1219
26. Widhalm K. Pediatric guidelines for lipid reduction. Eur Heart J. 1987; 8(suppl):65-70
27. West RJ, Lloyd JK. Use of cholestyramine in treatment of children with familial hypercholesterolemia. Arch Dis Child. 1973;48:370-374
28. Farah JR, Kwiterovich PO Jr, Neill CA. Dose-effect relation of cholestyramine in children and young adults with familial hypercholesterolemia. Lancet 1977;1:59-63
29. Glueck CJ, Fallat RW, Tsang RC. Pediatric familial type II hyperlipoproteinemia: therapy with diet and cholestyramine resin Pediatrics. 1973;52:669-679
30. Glueck CJ, Fallat RW, Tsang RC. Pediatric familial type II hyperlipoproteinemia: therapy with diet and cholestyramine resin for 24 to 36 months. Pediatrics. 1977;59:433-441
31. Glueck CJ, Mellies MJ, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics. 1986;78:338-348
32. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin and risk factor modification. JAMA. 1988;260: 2259-2263
33. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381
34. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92:78-82
35. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin Am J Cardiol. 1990;65:23F-26F
36. Frishman WH, Zimetbaum P, Nadelmann J. Lovastatin and other HMG-CoA reductase inhibitors. J Clin Pharmacol. 1989;29:975-982
37. Laue L, Hoeg JM, Barnes K, Loriaux DL, Chrousos GP. The effect of Mevinolin on steroidogenesis in patients with defects in the low-density lipoprotein receptor pathway. J Clin Endocrinol Metab. 1987;64:531-535
38. Srinivasan SR, Freedman DS, Sharma C, Webber LS, Berenson GS. Serum apolipoproteins A-1 and B in 2854 children from a biracial community: Bogalusa heart study. Pediatrics. 1986;78:189-200